Pharmaceutical companies will be required to disclose drug prices in television commercials in the United States under a new rule finalized by the Department of Health and Human Services.
According to Bloomberg, the rule will apply to medicines if the price for a month’s supply (or the usual course of therapy) before rebates and discounts is more than $35. The rule is part of an effort to help lower drug prices.
According to Health and Human Services Secretary Alex Azar, “Patients who are struggling with high drug costs are in that position because of the high list prices that drug companies set. Making those prices more transparent is a significant step in President Trump’s efforts to reform our prescription drug markets and put patients in charge of their own health care.”
The rule will go into effect 60 days after it’s published. Manufacturers Johnson & Johnson and Eli Lilly have already started including pricing information for ads for Xarelto (rivaroxaban) and Trulicity (dulaglutide), respectively.